Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease.
Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease. The company aims to create new medicines to leverage computing to make high throughput screening obsolete and cure diseases.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 29, 2022 | Series A | $50M | 1 |
ARCH Venture Partners
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
Yes | Series A |